PTSDの恐怖絶滅に対するオレキシン拮抗作用の影響
PTSD affects approximately 22% of Veterans who have served in Iraq and Afghanistan. Symptoms of PTSD may include re-experiencing, avoidance of trauma reminders, negative thoughts or feelings, and hyperarousal, such as increased startle reactivity and disturbed sleep. Treatments for PTSD are based on fear extinction principles in which individuals are repeatedly exposed a feared cue in the absence of danger, resulting in diminishing physiological reactions, a process believed to underlie recovery from PTSD. Studies suggest that orexin, a wake-promoting neuropeptide, may enhance fear extinction. This study will examine whether suvorexant, a selective orexin-receptor antagonist, will enhance fear extinction in Veterans with PTSD and insomnia. Finding a role for orexins in fear extinction will support the rationale for its further evaluation in the treatment of PTSD. Suvorexant is an accessible, safe medication that has been well-established in treating insomnia. It has outstanding promise for treating common and distressing symptoms in Veterans with PTSD.
調査の概要
詳細な説明
PTSD is a common consequence of combat manifested in part by trauma-related arousal and reactivity, seen in increased startle and impaired sleep that result from central and autonomic nervous system alterations. Impaired fear extinction may explain prolonged physiological alterations in PTSD. Preclinical evidence suggests that orexin, a wake-promoting neuropeptide, may be a shared mechanism underlying both sleep and fear extinction. While rodent studies have shown that pharmacological manipulations that block orexin in rodents facilitate fear extinction, no studies have tested this in humans with PTSD.
In line with the CSRD Combined Proof of Concept and Clinical Trial Merit Review Award mechanism, the investigators propose a proof-of-concept study leading to a clinical trial. During the initial phase, the investigators will develop and establish feasibility of the task and recruitment in 40 eligible participants with PTSD and insomnia. The task will involve a home-based multi-day remote fear conditioning experimental study, in which Veterans with PTSD and insomnia will receive nightly doses of suvorexant or placebo following extinction training over the subsequent 6 nights. Primary Aims of the proof of concept will be to: 1) establish remote fear conditioning procedures collaboratively with Veteran stakeholders; 2) evaluate enrollment, tolerability, adherence, and retention; 3) demonstrate fear conditioning and extinction learning using remote procedures; and 4) determine task feasibility of the home-based remote fear conditioning task. Go/No go milestones include: 1) the ability to enroll and randomize 40 participants by the end of month 23; 2) most participants (> 80%) will take medication as prescribed over 7 nights; 3) no SAEs during the course of treatment as determined by the data monitoring committee review (DMC); 4) < 10% of post-randomization participants will drop out (<4 participants), resulting in 36 individuals who complete all study procedures by month 23; 5) successful demonstration of measurement of fear conditioning (greater skin conductance (SC) responses to CS+ cues vs CS- cues) and fear extinction (differential SC responses to CS+ and CS- cues that diminish over trials) in the combined sample; 6) feasibility of the remote task demonstrated by <15% data loss due to recording issues (e.g., technical malfunction or UCS non-response in <6 participants).
If milestones are met, the investigators will advance to a clinical mechanistic trial to evaluate suvorexant in facilitating fear extinction using a double-blind randomized, placebo-controlled experimental design in Veterans with PTSD and insomnia. A total of 120 male and female Veterans with PTSD and insomnia will be randomized to either the suvorexant or placebo condition (n=60 in each condition). Participants will be trained in multi-day remote procedures involving fear conditioning (Day 1) and extinction 3 days later (Day 4), followed by 10 mg. suvorexant or placebo. A flexible dose titration of suvorexant (10-20 mg.) or matching placebo will be administered over the next 6 nights. Participants will then undergo extinction retention and fear reinstatement tests one week after extinction (Day 11). Primary outcome measures will be differential skin conductance responses to CS+ and CS- cues during extinction retention and reinstatement phases.
Primary Aims of the Clinical Trial will be: 1) To examine whether suvorexant facilitates fear extinction, seen as greater extinction retention compared to placebo. 2) To examine whether the facilitative effects of suvorexant are more resistant to reinstatement compared to placebo. Pending an effect of suvorexant on fear extinction retention and reinstatement, the investigators will evaluate whether improvement in insomnia mediates these effects. In-home sleep recording (including both sleep EEG and indices of sleep-disordered breathing) and sleep diary measures will be examined as secondary mediators. Greater improvement in sleep quality will partially account for greater extinction retention and less reinstatement. If successful, the proposed study will offer proof-of-concept data and meaningful guidance for future studies of suvorexant as an augmentation co-treatment in exposure therapy.
研究の種類
入学 (推定)
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前:Sabra S Inslicht, PhD
- 電話番号:3341 (415) 221-4810
- メール:sabra.inslicht@va.gov
研究場所
-
-
California
-
San Francisco、California、アメリカ、94121-1563
- 募集
- San Francisco VA Medical Center, San Francisco, CA
-
コンタクト:
- Sabra S Inslicht, PhD
- 電話番号:3341 (415) 221-4810
- メール:sabra.inslicht@va.gov
-
主任研究者:
- Sabra S Inslicht, PhD
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29401-5703
- まだ募集していません
- Ralph H. Johnson VA Medical Center, Charleston, SC
-
コンタクト:
- Lisa McTeague, PhD
- メール:McTeague@musc.edu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
(same for Phase 1 and Phase 2):
- men and women
- a history of US military service
- capable of reading and understanding English
- able to provide written informed consent
-
Criterion A event meets DSM-5 criteria and occurred during military service, including combat and military sexual trauma
-
Chronic full PTSD diagnosis >3 months duration as indexed by CAPS-5 at screening, and CAPS-5 score > 30
-
Insomnia indicated by insomnia severity index (ISI) score > 14
-
Subjects on non-exclusionary medications, and must be on a stable dose for at least 4 weeks prior to randomization, including Selective Serotonin Reuptake Inhibitors (SSRIs, e.g.,):
- sertraline
- paroxetine
- fluoxetine
- fluvoxamine
- citalopram
- escitalopram
-
Serotonin-norepinephrine reuptake inhibitors (SNRIs; e.g.):
- Desvenlafaxine
- Duloxetine
- Levomilnacipran
- Venlafaxine
-
For subjects who are in psychotherapy, treatment must be stable for 6 weeks
-
Women of child-bearing potential must not be pregnant or have plans for pregnancy or breastfeeding during the study and must use a medically acceptable method of birth control
Exclusion Criteria:
-
Moderate or severe DSM-5 alcohol or cannabis use disorder in the last 3 months
- Mild alcohol use disorder with abstinence of 30 days will be allowed
- Mild marijuana use disorder will be allowed with abstinence for one week prior to participation
- Any other DSM-5 drug use disorder in the last 3 months will be excluded
-
Lifetime bipolar disorder I or II, schizophrenia, schizoaffective disorder, obsessive-compulsive disorder, or major depressive disorder with psychotic features
-
Exposure to trauma in the last 3 months
-
Use of exclusionary antidepressant (trazodone, mirtazapine, doxepin, tricyclics), mood stabilizers (e.g., lithium), antipsychotic medication
-
Prominent suicidal or homicidal ideation or any suicidal behavior in the past 3 months on the Columbia Suicide Severity Rating Scale (C-SSRS) or increased risk of suicide that necessitates additional therapy or inpatient treatment
-
Pre-existing moderate sleep apnea or positive screen for sleep apnea by type III device (AHI>15) in the absence of adherence to effective treatment (such as CPAP or oral device)
-
Night shift work or extreme morning or evening tendencies in order to avoid the impact of circadian factors on subjective and objective sleep measures
-
Neurologic disorder or systemic illness affecting CNS function
-
Chronic or unstable medical illness, including:
- unstable angina
- myocardial infarction within the past 6 months
- congestive heart failure
- preexisting hypotension or orthostatic hypotension
- heart block or arrhythmia
- chronic renal or hepatic failure
- pancreatitis
- severe chronic obstructive pulmonary disease
-
History of severe traumatic brain injury as assessed by the Ohio State University Traumatic Brain Injury Identification Method (OSU-TBI ID)
-
Uncorrected hearing impairment
-
Mild cognitive impairment assessed by the Montreal Cognitive Assessment (MOCA)
-
Pregnancy, breastfeeding and/or refusal to use effective birth control (for women)
-
Previous adverse reaction to a hypnotic
-
Current use of benzodiazepines, strong inhibitors of CYP3A, or Digoxin
- The investigators will require that all participants do not consume heavy amounts of alcohol per week (>7 drinks for women, >14 drinks for men) or use illicit drugs for one week prior to participation
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Suvorexant
Suvorexant pills (10-20 milligrams) |
Suvorexant pills (10-20 milligrams) |
|
プラセボコンパレーター:Placebo
Matching placebo pills |
Matching placebo pills |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Enrollment
時間枠:Month 4-23
|
Goal of enrolling 40 individuals to achieve a total of 30 completers by the end of month 23. |
Month 4-23
|
|
Medication Adherence
時間枠:Month 4-23
|
Pill count and adherence to instructions over 7 study nights |
Month 4-23
|
|
Side effect reports
時間枠:Month 4-23
|
Serious Adverse Events (SAEs) |
Month 4-23
|
|
Post-randomization drop out
時間枠:Month 4-23
|
Post-randomization drop-out rates |
Month 4-23
|
|
Fear conditioning and extinction
時間枠:Month 4-23
|
Fear conditioning (greater SC responses to CS+ cues vs CS- cues) and fear extinction (differential SC responses to CS+ and CS- cues that diminish over repeated trials) in the combined sample |
Month 4-23
|
|
Rates of technical malfunction
時間枠:Month 4-23
|
Rates of technical malfunction (SC levels that are missing or <.02 microsiemens) and or non-responding to the UCS (e.g., SCR<.05 microsiemens) |
Month 4-23
|
|
Electrodermal Activity
時間枠:Years 2-7
|
Differential SC responses to CS+ and CS- cues during extinction retention and 2) during reinstatement. |
Years 2-7
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Insomnia Severity Index
時間枠:Years 2-7
|
Self-reported sleep |
Years 2-7
|
|
Sleep Electroencephalogram (EEG)
時間枠:Years 2-7
|
Total sleep time, rapid eye movement (REM) |
Years 2-7
|
協力者と研究者
捜査官
- 主任研究者:Sabra S Inslicht, PhD、San Francisco VA Medical Center, San Francisco, CA
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- MHBP-006-24S
- 1I01CX002734-01A2 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。